Wild, Damian; Fani, Melpomeni; Fischer, Richard; Del Pozzo, Luigi; Kaul, Felix; Krebs, Simone; Fischer, Richard; Rivier, Jean E F; Reubi, Jean-Claude; Maecke, Helmut R; Weber, Wolfgang A (2014). Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of nuclear medicine, 55(8), pp. 1248-1252. Society of Nuclear Medicine 10.2967/jnumed.114.138834
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
J Nucl Med-2014-Wild-1248-52.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (790kB) | Request a copy |
Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 consecutive patients with advanced neuroendocrine tumors, we evaluated whether treatment with (177)Lu-labeled sst antagonists is feasible.
METHODS
After injection of approximately 1 GBq of (177)Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2] ((177)Lu-DOTA-JR11) and (177)Lu-DOTATATE, 3-dimensional voxel dosimetry analysis based on SPECT/CT was performed. A higher tumor-to-organ dose ratio for (177)Lu-DOTA-JR11 than for (177)Lu-DOTATATE was the prerequisite for treatment with (177)Lu-DOTA-JR11.
RESULTS
Reversible minor adverse effects of (177)Lu-DOTA-JR11 were observed. (177)Lu-DOTA-JR11 showed a 1.7-10.6 times higher tumor dose than (177)Lu-DOTATATE. At the same time, the tumor-to-kidney and tumor-to-bone marrow dose ratio was 1.1-7.2 times higher. All 4 patients were treated with (177)Lu-DOTA-JR11, resulting in partial remission in 2 patients, stable disease in 1 patient, and mixed response in the other patient.
CONCLUSION
Treatment of neuroendocrine tumors with radiolabeled sst antagonists is clinically feasible and may have a significant impact on peptide receptor radionuclide therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Reubi-Kattenbusch, Jean-Claude |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0161-5505 |
Publisher: |
Society of Nuclear Medicine |
Language: |
English |
Submitter: |
Doris Haefelin |
Date Deposited: |
07 Apr 2015 16:07 |
Last Modified: |
05 Dec 2022 14:45 |
Publisher DOI: |
10.2967/jnumed.114.138834 |
PubMed ID: |
24963127 |
Uncontrolled Keywords: |
antagonists, neuroendocrine tumors, somatostatin receptor targeting |
BORIS DOI: |
10.7892/boris.66501 |
URI: |
https://boris.unibe.ch/id/eprint/66501 |
Actions (login required)
 |
Edit item |